Document is current

Article History

Received: 12 October 2023

Accepted: 22 October 2024

First Online: 6 November 2024

Competing interests

: J.J.F., K.H., S.J.R., J.J., J.G., L.A.W., and G.T.D. are current employees of Quiver Bioscience and may hold stock options in Quiver Bioscience. D.G. was an employee of Q-State Bioscience, is currently a consultant for Quiver Bioscience and has received stock options in Quiver Bioscience. E.N., C.F., M.B., B.F. are current employees of Vertex Pharmaceuticals Inc. and hold stock in Vertex Pharmaceuticals Inc. N.D.B. is a former employee of Q-State Biosciences and may be an inventor on relevant patents, but holds no financial stake, stock, or options. M.F.B. is a co-founder of Allos Pharma, and a consultant and owner of stock options for Addex Therapeutics and Luminopia. H.U. and H.S. are current employees of Wave Life Sciences and report stock ownership in Wave Life Sciences. R.P.D. was employed at Vertex Pharmaceuticals at the time of the study, is a current employee of Intellia Therapeutics, and reports stock ownership in Intellia Therapeutics. Elizabeth Berry-Kravis has received funding from Acadia, Alcobra, AMO, Asuragen, Avexis, Biogen, BioMarin, Cydan, Engrail, Erydel, Fulcrum, GeneTx, GW, Healx, Ionis, Jaguar, Kisbee, Lumos, Marinus, Moment Biosciences, Neuren, Neurogene, Neurotrope, Novartis, Orphazyme/Kempharm, Ovid, PTC Therapeutics, Retrophin, Roche, Seaside Therapeutics, Taysha, Tetra, Ultragenyx, Yamo, Zynerba, and Vtesse/Sucampo/Mallinckrodt Pharmaceuticals, to consult on trial design or run clinical or lab validation trials in genetic neurodevelopmental or neurodegenerative disorders, all of which is directed to RUMC in support of rare disease programs; B.-K. receives no personal funds and RUMC has no relevant financial interest in any of the commercial entities listed.